ArrePath was founded upon the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state-of-the-art technologies and novel strategies.
We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues.
Our advanced machine learning (ML) and imaging-based drug discovery platform enable rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of the mechanism of action at the outset of the discovery process.
Total Funding: N/A
Funding Stage: N/A
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: N/A
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at ArrePath
Lloyd Payne
Chief Executive Officer
Senior Software Engineer
Princeton, New Jersey
Senior Software Engineer
Princeton, New Jersey
Technical Lead Chemical ML
Princeton, New Jersey
Senior Scientist
Princeton, New Jersey